Azacitidine Is Effective in Patients with Low Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry

被引：0
|
作者：
Garcia, Regina [1 ]
de Miguel, Dunia [2 ]
Bernal, Maria-Teresa [3 ]
Tormo, Mar [4 ]
Sanz, Guillermo [5 ]
de Paz, Raquel [6 ]
Figueredo, Antonio [7 ]
Amutio, Maria E. [8 ]
Guzman, Jose L. [9 ]
机构：
[1] Hosp Virgen Victoria, Malaga, Spain
[2] Hosp Univ Guadalaja, Madrid, Spain
[3] PETHEMA Grp, Oviedo, Spain
[4] Hosp Clin, Valencia, Spain
[5] Hosp Univ La Fe, Valencia, Spain
[6] Hosp Univ La Paz, Madrid, Spain
[7] Hosp Virgen Macarena, Seville, Spain
[8] Hosp Cruces, Bilbao, Spain
[9] Hosp SAS Jerez de la Frontera, Jerez de la Frontera, Spain
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1462 / 1462
页数：1
相关论文
共 50 条
  • [21] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    BLOOD, 2017, 130
  • [22] Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
    Abaza, Yasmin
    Hidalgo-Lopez, Juliana E.
    Verstovsek, Srdan
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Estrov, Zeev
    Alvarado, Yesid
    Burger, Jan
    Schneider, Heather
    Soltysiak, Kelly A.
    Wei, Yue
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    LEUKEMIA RESEARCH, 2018, 73 : 78 - 85
  • [23] ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study
    Platzbecker, Uwe
    Germing, Ulrich
    Giagounidis, Aristoteles
    Goetze, Katharina
    Kiewe, Philipp
    Mayer, Karin
    Ottman, Oliver
    Radsak, Markus P.
    Wolff, Thomas
    Haase, Detlef
    Hankin, Monty
    Wilson, Dawn M.
    Laadem, Adberrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    BLOOD, 2014, 124 (21)
  • [24] LONG TERM FOLLOW UP OF 5 PATIENTS TREATED WITH MESENCHYMAL STROMAL CELL IMMUNOMODULATORY THERAPY FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME
    Tan, D.
    Carnley, B.
    Sturm, M.
    Cirillo, M.
    CYTOTHERAPY, 2024, 26 (06) : S40 - S40
  • [25] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Haase, D.
    Hankin, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M.
    Attie, K.
    HAEMATOLOGICA, 2015, 100 : 192 - 192
  • [26] 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
    Musto, P.
    Maurillo, L.
    Spagnoli, A.
    Gozzini, A.
    Rivellini, F.
    Tatarelli, C.
    Lunghi, M.
    Fili, C.
    Orciuolo, E.
    Ciuffreda, L.
    Vigna, E.
    Della Cioppa, P.
    Ferrero, D.
    Palmieri, S.
    Palumbo, G.
    Di Renzo, N.
    Oliva, E.
    Sanpaolo, G.
    Pastore, D.
    Tonso, A.
    Santagostino, A.
    Villani, O.
    D'Auria, F.
    D'Arco, A.
    Gaidano, G.
    Galimberti, S.
    Russo, D.
    Venditti, A.
    Aloe-Spiriti, M. A.
    Leone, G.
    Santini, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [27] Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry
    Comont, Thibault
    Heiblig, Mael
    Riviere, Etienne
    Terriou, Louis
    Rossignol, Julien
    Bouscary, Didier
    Rieu, Virginie
    Le Guenno, Guillaume
    Mathian, Alexis
    Aouba, Achille
    Vinit, Julien
    Dion, Jeremie
    Kosmider, Olivier
    Terrier, Benjamin
    Georgin-Lavialle, Sophie
    Fenaux, Pierre
    Mekinian, Arsene
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 969 - 974
  • [28] Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups
    Reinwald, Mark
    Nowak, Daniel
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Goetze, Katharina S.
    Ottmann, Oliver G.
    Haase, Detlef
    Shirneshan, Katayoon
    Schlenk, Richard F.
    Letsch, Anne
    Luebbert, Michael
    Ganser, Arnold
    Nowak, Verena
    Fey, Stephanie
    Oblaender, Julia
    Mossner, Maximilian
    Germing, Ulrich
    Hofmann, Wolf-Karsten
    Nolte, Florian
    BLOOD, 2012, 120 (21)
  • [29] EFFICACY AND SAFETY OF THE USE OF LENALIDOMIDE IN PATIENTS SUFFERING FROM MYELODYSPLASTIC SYNDROME WITHOUT DELETION OF 5Q DATA OF THE SPANISH REGISTRY OF SMD
    Sanchez Garcia, J.
    Diez Campelo, M.
    Ramos, F.
    Andreu, R.
    Santiago, O.
    Josefina, S.
    Javier, C.
    Sanz, G.
    HAEMATOLOGICA, 2015, 100 : 22 - 22
  • [30] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Naomi Galili
    Deborah Mulford
    Scott E Smith
    Gail L Brown
    David P Steensma
    Roger M Lyons
    Ralph Boccia
    Mikkael A Sekeres
    Guillermo Garcia-Manero
    Ruben A Mesa
    Journal of Hematology & Oncology, 5
12345